The usefulness of NfL as a surrogate marker of neurodegenerative disease and its complementary value to other biomarkers within the ATN framework largely depend on the pathophysiological substrate of increases in plasma NfL concentration. The gene discussed is NEFL; the disease is neurodegenerative disease.